Hepatocellular Carcinoma in Primary Biliary Cholangitis

Hepatocellular carcinoma (HCC) is potentially fatal complication affecting patients with primary biliary cholangitis (PBC). The incidence of HCC is 13 per 1000 person-years in patients with PBC cirrhosis, but much lower at 2.7 per 1000 person-years among patients with PBC without cirrhosis. Risk fac...

Full description

Saved in:

Bibliographic Details
Published in:	Clinics in liver disease Vol. 26; no. 4; pp. 691 - 704
Main Authors:	Sy, Alexander M., Ferreira, Raphaella D., John, Binu V.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-11-2022
Subjects:	Autoimmune liver disease Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - etiology Cholagogues and Choleretics - therapeutic use Cholangitis Cirrhosis Epidemiology Humans Liver Cirrhosis, Biliary - complications Liver Cirrhosis, Biliary - drug therapy Liver Cirrhosis, Biliary - epidemiology Liver Neoplasms - epidemiology Liver Neoplasms - etiology Male Primary liver cancer Ursodeoxycholic Acid - therapeutic use Cirrhosis Autoimmune liver disease Primary liver cancer Epidemiology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hepatocellular carcinoma (HCC) is potentially fatal complication affecting patients with primary biliary cholangitis (PBC). The incidence of HCC is 13 per 1000 person-years in patients with PBC cirrhosis, but much lower at 2.7 per 1000 person-years among patients with PBC without cirrhosis. Risk factors for the development of HCC in PBC include the presence of advanced fibrosis or cirrhosis and male sex, with some studies suggesting that treatment with ursodeoxycholic acid (UDCA) and UDCA response may reduce risk.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1089-3261 1557-8224
DOI:	10.1016/j.cld.2022.06.011